ATE512989T1 - Verfahren zur herstellung von scdb-bibliotheken - Google Patents

Verfahren zur herstellung von scdb-bibliotheken

Info

Publication number
ATE512989T1
ATE512989T1 AT03717592T AT03717592T ATE512989T1 AT E512989 T1 ATE512989 T1 AT E512989T1 AT 03717592 T AT03717592 T AT 03717592T AT 03717592 T AT03717592 T AT 03717592T AT E512989 T1 ATE512989 T1 AT E512989T1
Authority
AT
Austria
Prior art keywords
libraries
scdb
producing
antigen
constructed
Prior art date
Application number
AT03717592T
Other languages
English (en)
Inventor
Tetsuo Kojima
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE512989T1 publication Critical patent/ATE512989T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Liquid Crystal Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Automatic Tape Cassette Changers (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
AT03717592T 2002-04-15 2003-04-15 Verfahren zur herstellung von scdb-bibliotheken ATE512989T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002112369 2002-04-15
PCT/JP2003/004773 WO2003087163A1 (en) 2002-04-15 2003-04-15 METHOD OF CONSTRUCTING scDb LIBRARY

Publications (1)

Publication Number Publication Date
ATE512989T1 true ATE512989T1 (de) 2011-07-15

Family

ID=29243316

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03717592T ATE512989T1 (de) 2002-04-15 2003-04-15 Verfahren zur herstellung von scdb-bibliotheken

Country Status (6)

Country Link
US (1) US8030461B2 (de)
EP (1) EP1500665B1 (de)
JP (1) JP4386741B2 (de)
AT (1) ATE512989T1 (de)
AU (1) AU2003227504A1 (de)
WO (1) WO2003087163A1 (de)

Families Citing this family (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1500665B1 (de) 2002-04-15 2011-06-15 Chugai Seiyaku Kabushiki Kaisha VERFAHREN ZUR HERSTELLUNG VON scDb-BIBLIOTHEKEN
US8158385B2 (en) * 2002-10-11 2012-04-17 Chugai Seiyaku Kabushiki Kaisha Cell death-inducing agent
US8337841B2 (en) 2003-01-21 2012-12-25 Chugai Seiyaku Kabushiki Kaisha Methods of screening for antibody light chains
JP4794301B2 (ja) * 2003-06-11 2011-10-19 中外製薬株式会社 抗体の製造方法
AU2003271174A1 (en) * 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
AU2003271186A1 (en) * 2003-10-14 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
US20070281327A1 (en) * 2003-12-12 2007-12-06 Kiyotaka Nakano Methods of Screening for Modified Antibodies With Agonistic Activities
EP1710255A4 (de) * 2003-12-12 2008-09-24 Chugai Pharmaceutical Co Ltd Modifizierte antikörper, die rezeptortrimere oder höhere multimere erkennen
KR20060130606A (ko) * 2003-12-12 2006-12-19 추가이 세이야쿠 가부시키가이샤 세포사 유도제
TW200530269A (en) 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
US20080274110A1 (en) * 2004-04-09 2008-11-06 Shuji Ozaki Cell Death-Inducing Agents
JP5057967B2 (ja) * 2005-03-31 2012-10-24 中外製薬株式会社 ｓｃ（Ｆｖ）２構造異性体
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
EP2824183B1 (de) * 2005-04-08 2020-07-29 Chugai Seiyaku Kabushiki Kaisha Verfahren zur Herstellung bispezifischer Antikörper
CN101237890A (zh) 2005-06-10 2008-08-06 中外制药株式会社 含有葡甲胺的蛋白质制剂的稳定剂及其利用
US20090028854A1 (en) * 2005-06-10 2009-01-29 Chugai Seiyaku Kabushiki Kaisha sc(Fv)2 SITE-DIRECTED MUTANT
JP5085322B2 (ja) 2005-06-10 2012-11-28 中外製薬株式会社 ｓｃ（Ｆｖ）２を含有する医薬組成物
JP5144499B2 (ja) 2006-03-31 2013-02-13 中外製薬株式会社 二重特異性抗体を精製するための抗体改変方法
EP4793360A2 (de) 2006-03-31 2026-08-19 Chugai Seiyaku Kabushiki Kaisha Verfahren zur kontrolle der blut-pharmazeutizität von antikörpern
WO2008007755A1 (en) * 2006-07-13 2008-01-17 Chugai Seiyaku Kabushiki Kaisha Cell death inducer
EP3127921A1 (de) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Verfahren zur modifizierung eines isoelektrischen punkts eines antikörpers über aminosäuresubstition in cdr
CA2706425A1 (en) * 2007-11-27 2009-06-04 Ablynx N.V. Method for obtaining polypeptide constructs comprising two or more single domain antibodies
LT2361936T (lt) * 2010-02-25 2016-09-12 Affimed Gmbh Antigeną rišanti molekulė ir jos panaudojimas
CN105859889B (zh) 2010-11-17 2020-01-07 中外制药株式会社 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
AU2011373925B2 (en) * 2011-07-22 2016-04-28 Affimed Therapeutics Ag Multivalent antigen-binding Fv molecule
CA2925256C (en) 2013-09-27 2023-08-15 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
UA122479C2 (uk) 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
PL3099717T3 (pl) 2014-01-31 2019-10-31 Novartis Ag Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie
EA201691765A1 (ru) 2014-03-14 2016-12-30 Новартис Аг Молекулы антител против lag-3 и их применения
CN122399016A (zh) 2014-03-15 2026-07-17 诺华股份有限公司 使用嵌合抗原受体治疗癌症
MX2016017393A (es) 2014-07-01 2017-09-05 Pfizer Diacuerpos heterodimericos biespecificos y sus usos.
JP2017528433A (ja) 2014-07-21 2017-09-28 ノバルティス アーゲー 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
AU2015292744C1 (en) 2014-07-21 2021-01-21 Novartis Ag Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
WO2016014553A1 (en) 2014-07-21 2016-01-28 Novartis Ag Sortase synthesized chimeric antigen receptors
JP6831777B2 (ja) 2014-07-21 2021-02-17 ノバルティス アーゲー Ｃｄ３３キメラ抗原受容体を使用する癌の処置
WO2016019300A1 (en) 2014-07-31 2016-02-04 Novartis Ag Subset-optimized chimeric antigen receptor-containing t-cells
EP3180359A1 (de) 2014-08-14 2017-06-21 Novartis AG Behandlung von krebs mit einem chimären gfr-alpha-4-antigenrezeptor
EP3712171A1 (de) 2014-08-19 2020-09-23 Novartis AG Behandlung von krebs mit einem chimären cd123-antigenrezeptor
US10577417B2 (en) 2014-09-17 2020-03-03 Novartis Ag Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
TWI701435B (zh) 2014-09-26 2020-08-11 日商中外製藥股份有限公司 測定ｆｖｉｉｉ的反應性之方法
TWI700300B (zh) 2014-09-26 2020-08-01 日商中外製藥股份有限公司 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
SG11201702401RA (en) 2014-10-14 2017-04-27 Novartis Ag Antibody molecules to pd-l1 and uses thereof
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
PL3280729T3 (pl) 2015-04-08 2022-08-22 Novartis Ag Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19
WO2016172583A1 (en) 2015-04-23 2016-10-27 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
US20180340025A1 (en) 2015-07-29 2018-11-29 Novartis Ag Combination therapies comprising antibody molecules to lag-3
EP3328418A1 (de) 2015-07-29 2018-06-06 Novartis AG Kombinationstherapien mit antikörpermolekülen gegen pd-1
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
CN108697794A (zh) 2015-12-17 2018-10-23 诺华股份有限公司 C-met抑制剂和抗pd-1抗体分子的组合及其用途
CN108495651A (zh) 2015-12-17 2018-09-04 诺华股份有限公司 抗pd-1的抗体分子及其用途
PT3393504T (pt) 2015-12-22 2025-12-30 Novartis Ag Recetor de antigénio quimérico (car) de mesotelina e anticorpo contra o inibidor de pd-l1 para utilização combinada em terapia anticancerígena
US20200270363A1 (en) 2015-12-25 2020-08-27 Chugai Seiyaku Kabushiki Kaisha Antibody having enhanced activity, and method for modifying same
SG11201803989WA (en) 2015-12-28 2018-06-28 Chugai Pharmaceutical Co Ltd Method for promoting efficiency of purification of fc region-containing polypeptide
EP3851457A1 (de) 2016-01-21 2021-07-21 Novartis AG Gegen cll-1 gerichtete multispezifische moleküle
SG11201807489PA (en) 2016-03-04 2018-09-27 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
EP3432924A1 (de) 2016-03-23 2019-01-30 Novartis AG Zellsekretierte minikörper und verwendungen davon
US20230071283A1 (en) 2016-04-15 2023-03-09 Aimee S. Payne Compositions and methods for selective protein expression
AU2017255077B2 (en) 2016-04-28 2024-05-16 Chugai Seiyaku Kabushiki Kaisha Antibody-containing preparation
WO2017210617A2 (en) 2016-06-02 2017-12-07 Porter, David, L. Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
EP3484455A2 (de) 2016-07-15 2019-05-22 Novartis AG Behandlung und prävention von zytokin-freisetzungssyndrom unter verwendung eines chimären antigenrezeptors in kombination mit einem kinasehemmer
KR20230100748A (ko) 2016-07-28 2023-07-05 노파르티스 아게 키메라 항원 수용체 및 pd-1 억제제의 조합 요법
CA3027018A1 (en) 2016-07-29 2018-02-01 Chugai Seiyaku Kabushiki Kaisha Bispecific antibody exhibiting increased alternative fviii-cofactor-function activity
SG11201900885VA (en) 2016-08-01 2019-02-27 Novartis Ag Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
US11352438B2 (en) 2016-09-06 2022-06-07 Chugai Seiyaku Kabushiki Kaisha Methods of using a bispecific antibody that recognizes coagulation factor IX and/or activated coagulation factor IX and coagulation factor X and/or activated coagulation factor X
JP7467117B2 (ja) 2016-10-07 2024-04-15 ノバルティス アーゲー 癌の治療のためのキメラ抗原受容体
US11535662B2 (en) 2017-01-26 2022-12-27 Novartis Ag CD28 compositions and methods for chimeric antigen receptor therapy
WO2018160731A1 (en) 2017-02-28 2018-09-07 Novartis Ag Shp inhibitor compositions and uses for chimeric antigen receptor therapy
JP7209298B2 (ja) 2017-03-31 2023-01-20 公立大学法人奈良県立医科大学 血液凝固第ｖｉｉｉ因子の機能を代替する多重特異性抗原結合分子を含有する、血液凝固第ｉｘ因子異常症の予防および／または治療に用いられる医薬組成物
EP3615068A1 (de) 2017-04-28 2020-03-04 Novartis AG Auf bcma abzielender wirkstoff und kombinationstherapie mit einem gamma-sekretase-inhibitor
EP3615055A1 (de) 2017-04-28 2020-03-04 Novartis AG Zellen, die einen auf bcma abzielenden chimären antigenrezeptor exprimieren, und kombinationsbehandlung mit einem gamma-sekretase-inhibitor
MX2019015885A (es) 2017-06-22 2020-09-10 Novartis Ag Moleculas de anticuerpo que se unen a cd73 y usos de las mismas.
CN111050791A (zh) 2017-06-27 2020-04-21 诺华股份有限公司 用于抗tim-3抗体的给药方案及其用途
SG10201913147WA (en) 2017-07-11 2020-02-27 Compass Therapeutics Llc Agonist antibodies that bind human cd137 and uses thereof
WO2019018730A1 (en) 2017-07-20 2019-01-24 Novartis Ag DOSAGE REGIMES FOR ANTI-LAG3 ANTIBODIES AND USES THEREOF
CA3071236A1 (en) 2017-09-29 2019-04-04 Chugai Seiyaku Kabushiki Kaisha Multispecific antigen-binding molecule having blood coagulation factor viii (fviii) cofactor function-substituting activity, and pharmaceutical formulation containing said moleculeas active ingredient
US20210179709A1 (en) 2017-10-31 2021-06-17 Novartis Ag Anti-car compositions and methods
US11718679B2 (en) 2017-10-31 2023-08-08 Compass Therapeutics Llc CD137 antibodies and PD-1 antagonists and uses thereof
KR20260090008A (ko) 2017-11-01 2026-06-16 추가이 세이야쿠 가부시키가이샤 생물 활성이 저하된 항체 배리언트 및 아이소폼
MX2020004756A (es) 2017-11-16 2020-08-20 Novartis Ag Terapias de combinacion.
EP3713961A2 (de) 2017-11-20 2020-09-30 Compass Therapeutics LLC Cd137-antikörper und tumorantigenbindende antikörper sowie deren verwendung
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
AU2019215031C1 (en) 2018-01-31 2026-02-26 Novartis Ag Combination therapy using a chimeric antigen receptor
EP3765517A1 (de) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. An calreticulin bindende multifunktionsmoleküle und ihre verwendungen
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
US20210047405A1 (en) 2018-04-27 2021-02-18 Novartis Ag Car t cell therapies with enhanced efficacy
WO2019226658A1 (en) 2018-05-21 2019-11-28 Compass Therapeutics Llc Multispecific antigen-binding compositions and methods of use
CN112384534A (zh) 2018-05-21 2021-02-19 指南针制药有限责任公司 用于增强nk细胞对靶细胞的杀死的组合物和方法
US20210213063A1 (en) 2018-05-25 2021-07-15 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
IL279367B2 (en) 2018-06-13 2026-05-01 Novartis Ag BCMA chimeric antigen receptors and their uses
CA3104295A1 (en) 2018-06-19 2019-12-26 Atarga, Llc Antibody molecules to complement component 5 and uses thereof
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
JP2021531306A (ja) 2018-07-25 2021-11-18 アドバンスド アクセラレーター アプリケーションズ エスエー 神経内分泌腫瘍の処置の方法
JP7497351B2 (ja) 2018-11-13 2024-06-10 コンパス セラピューティクス リミテッド ライアビリティ カンパニー チェックポイント分子に対する多重特異性結合性構築物およびその使用
AU2019402189B2 (en) 2018-12-20 2023-04-13 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
US20210386763A1 (en) 2018-12-20 2021-12-16 Novartis Ag Pharmaceutical combinations
EP3924054B1 (de) 2019-02-15 2025-04-02 Novartis AG 3-(1-oxo-5- (piperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dionderivate und ihre verwendungen
CA3123519A1 (en) 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US10871640B2 (en) 2019-02-15 2020-12-22 Perkinelmer Cellular Technologies Germany Gmbh Methods and systems for automated imaging of three-dimensional objects
JP7579795B2 (ja) 2019-02-21 2024-11-08 マレンゴ・セラピューティクス，インコーポレーテッド ＮＫｐ３０に結合する抗体分子およびその使用
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
EP3927371A1 (de) 2019-02-22 2021-12-29 Novartis AG Kombinationstherapien von chimären egfrviii-antigenrezeptoren und pd-1-inhibitoren
PH12021552414A1 (en) 2019-03-29 2022-07-25 Atarga Llc Anti fgf23 antibody
CN114786679A (zh) 2019-10-21 2022-07-22 诺华股份有限公司 具有维奈托克和tim-3抑制剂的组合疗法
WO2021079195A1 (en) 2019-10-21 2021-04-29 Novartis Ag Tim-3 inhibitors and uses thereof
WO2021108661A2 (en) 2019-11-26 2021-06-03 Novartis Ag Chimeric antigen receptors and uses thereof
US20230057071A1 (en) 2019-12-20 2023-02-23 Novartis Ag Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
WO2021138474A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
CN115298322A (zh) 2020-01-17 2022-11-04 贝克顿迪金森公司 用于单细胞分泌组学的方法和组合物
EP4090335A1 (de) 2020-01-17 2022-11-23 Novartis AG Kombination aus einem tim-3-inhibitor und einem hypomethylierungsmittel zur verwendung bei der behandlung von myelodysplastischem syndrom oder chronischer myelomonozytischer leukämie
IL295878A (en) 2020-02-27 2022-10-01 Novartis Ag Methods for producing cells expressing a chimeric antigen receptor
EP4168007A1 (de) 2020-06-23 2023-04-26 Novartis AG Dosierschema mit 3-(1-oxoisoindolin-2-yl)piperidin-2,6-dion-derivaten
CA3176556A1 (en) 2020-07-16 2022-01-20 Novartis Ag Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
WO2022026592A2 (en) 2020-07-28 2022-02-03 Celltas Bio, Inc. Antibody molecules to coronavirus and uses thereof
EP4188549A1 (de) 2020-08-03 2023-06-07 Novartis AG Heteroarylsubstituierte 3-(1-oxoisoindolin-2-yl)piperidin-2,6-dionderivate und verwendungen davon
WO2022043558A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
US20230321285A1 (en) 2020-08-31 2023-10-12 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
WO2022097065A2 (en) 2020-11-06 2022-05-12 Novartis Ag ANTIBODY Fc VARIANTS
KR20230107617A (ko) 2020-11-13 2023-07-17 노파르티스 아게 키메라 항원 수용체(car)-발현 세포를 사용한 병용 요법
EP4284510A1 (de) 2021-01-29 2023-12-06 Novartis AG Dosierungsschemata für anti-cd73- und anti-enpd2-antikörper und verwendungen davon
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
WO2023044483A2 (en) 2021-09-20 2023-03-23 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
TW202342548A (zh) 2022-02-07 2023-11-01 美商威特拉公司 抗獨特型(anti-idiotype)抗體分子及其用途
WO2023220695A2 (en) 2022-05-13 2023-11-16 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
CA3263767A1 (en) 2022-08-03 2024-02-08 Voyager Therapeutics, Inc. COMPOSITIONS AND PROCESSES ALLOWING CROSSING THE BLOOD-BRAIN BARRIER
WO2024168061A2 (en) 2023-02-07 2024-08-15 Ayan Therapeutics Inc. Antibody molecules binding to sars-cov-2
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2026036047A1 (en) 2024-08-08 2026-02-12 Altus Enterprises, Inc. Antibody molecules to fixa and fx and uses thereof
US20260167709A1 (en) 2024-09-11 2026-06-18 Novartis Ag Antibodies targeting il-31
WO2026102093A1 (en) 2024-11-07 2026-05-15 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2026151679A1 (en) 2025-01-07 2026-07-16 Compass Therapeutics, Llc. Multispecific binding constructs targeting pd-1 and vegf and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE295895T1 (de) 1992-03-11 2005-06-15 Powderject Vaccines Inc Genetischer impfstoff gegen den immunschwäche virus
EP0871673B1 (de) 1995-05-03 2006-04-05 Bioenhancementsments Ltd. Bispezifische antikörper in denen die bindungsfähigkeit durch eine mittels licht spaltbare gruppe reversibel inhibiert wird
EP0979281B1 (de) 1997-05-02 2005-07-20 Genentech, Inc. ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
DE19819846B4 (de) * 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
US6897044B1 (en) 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
AU2578401A (en) 1999-12-14 2001-06-25 Burnham Institute, The Bcl-g polypeptides, encoding nucleic acids and methods of use
JP2003527849A (ja) 2000-03-22 2003-09-24 キュラゲン コーポレイション 新規ペプチド及びこれをコードする核酸
JP4303105B2 (ja) 2001-06-28 2009-07-29 ドマンティス リミテッド 二重特異性リガンドとその利用
EP1500665B1 (de) 2002-04-15 2011-06-15 Chugai Seiyaku Kabushiki Kaisha VERFAHREN ZUR HERSTELLUNG VON scDb-BIBLIOTHEKEN
US8337841B2 (en) 2003-01-21 2012-12-25 Chugai Seiyaku Kabushiki Kaisha Methods of screening for antibody light chains
JP4794301B2 (ja) 2003-06-11 2011-10-19 中外製薬株式会社 抗体の製造方法

Also Published As

Publication number Publication date
AU2003227504A1 (en) 2003-10-27
JPWO2003087163A1 (ja) 2005-08-18
US20070087381A1 (en) 2007-04-19
EP1500665B1 (de) 2011-06-15
EP1500665A1 (de) 2005-01-26
WO2003087163A1 (en) 2003-10-23
JP4386741B2 (ja) 2009-12-16
EP1500665A4 (de) 2006-05-24
US8030461B2 (en) 2011-10-04

Similar Documents

Publication Publication Date Title
AU2003227504A1 (en) METHOD OF CONSTRUCTING scDb LIBRARY
DE60325188D1 (de) Verfahren zur herstellung von sterilen, stabilisierten nanodispersionen
DE602004020538D1 (de) Verfahren und Vorrichtung zur Laserbestrahlung, sowie Verfahren zur Herstellung von Halbleiter.
DE60317651D1 (de) Verfahren zur herstellung von hochmolekularen verbindungen für photoresists
DE60312970D1 (de) Verfahren zur herstellung von gefärbten artikeln
ATE453648T1 (de) Verfahren zur herstellung von hexahydrofuroc2,3- büfuran-3-ol
DE60236402D1 (de) Verfahren zur Herstellung von Halbleitervorrichtungen
ATE469908T1 (de) Verfahren zur herstellung von pimecrolimus
ATE286011T1 (de) Verfahren zur herstellung von 1-octen
ATE374463T1 (de) Verfahren zur herstellung von oxazolidinonen
DE50305969D1 (de) Verfahren zur herstellung eines kurzkanal-feldeffekttransistors
DE60327788D1 (de) Verfahren zur herstellung von polytrimethylenterephthalt-fasern
ATE506351T1 (de) Verfahren zur herstellung von 10,11-dihydro-10- oxo-5h-dibenzoäb,füazepin-5-carboxamid
ATE553103T1 (de) Verfahren zur herstellung von (s)-pantoprazol
ATE358172T1 (de) Verfahren zur herstellung von olefinen.
ATE328010T1 (de) Verfahren zur herstellung von polyisobuten
ATE360610T1 (de) Verfahren zur herstellung von cilastatin
ATE548348T1 (de) Verfahren zur herstellung des r,r (oder s,s) konfigurierten glycopyrronium-stereoisomers
ATE323677T1 (de) Verfahren zur herstellung von 4-amino-2,5- bisheterocyclylchinazolinen
DE60334180D1 (de) Verfahren zur Herstellung einer Radlaufschale und damit hergestellte Radlaufschale
ATE402138T1 (de) Verfahren zur herstellung von 2- aminoindanderivaten
DE502004004246D1 (de) Verfahren zur herstellung von hochreinen, tris- und bis-ortho-metallierten organometall-verbindungen
DE50107372D1 (de) Verfahren zur herstellung von glasfliesen, glasbordüren, glasdekorpaneelen oder dgl.
ATE437879T1 (de) Verfahren zur herstellung von imipenem
ATE371642T1 (de) Verfahren zur herstellung von 3- methylthiopropanal

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties